Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

To assess the role of interleukin-1 (IL-1) in cutaneous leishmaniasis, Leishmania major-infected mice were treated with an anti-IL-1 receptor monoclonal antibody, LA-15.6. MoAb LA-15.6 prevents binding of IL-1 to both the T cell and B cell/macrophage forms of the IL-1 receptor. We found that treating with LA 15.6 inhibited the development of cutaneous lesions of L. major in both genetically-susceptible and resistant mice. Interestingly, this treatment had little or no effect on parasite numbers in the lesions or on the cytokines (interferon-gamma, interleukin-4) that the animals produced in response to infection with the parasite. These results suggest that although IL-1 plays a detrimental role in cutaneous leishmaniasis, it does not mediate this effect by altering the parasite-specific T cell response.

Original publication





Parasite immunology

Publication Date





571 - 577


Department of Tropical Public Health, Harvard School of Public Health, Boston, MA 02115.


Lymph Nodes, Animals, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Leishmania major, Parasitemia, Leishmaniasis, Cutaneous, Disease Models, Animal, Receptors, Interleukin-1, Interleukin-1, Antibodies, Monoclonal, Cytokines, Lymphocyte Activation